Morgan Stanley An2 Therapeutics, Inc. Transaction History

Morgan Stanley

$1.59 Trillion
Q3 2025

A detailed history of Morgan Stanley transactions in An2 Therapeutics, Inc. stock. As of the latest transaction made, Morgan Stanley holds 190,770 shares of ANTX stock, worth $217,477. This represents 0.0% of its overall portfolio holdings.

Number of Shares

190,770

Previous 178,243 7.03%

Holding current value

$217,477

Previous $188,000 28.72%

% of portfolio

0.0%

Previous 0.0%

22 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2025 Nov 14, 2025	BUY	$1.05 - $1.34 $13,153 - $16,786	12,527 Added 7.03%	190,770 $242,000
Q2 2025 Aug 15, 2025	BUY	$1.06 - $1.4 $188,619 - $249,120	177,943 Added 59314.33%	178,243 $188,000
Q4 2024 Feb 14, 2025	SELL	$1.0 - $1.67 $3 - $5	-3 Reduced 0.99%	300 $0
Q3 2024 May 14, 2025	SELL	$0.98 - $2.96 $16,814 - $50,787	-17,158 Reduced 98.26%	303 $0
Q3 2024 Nov 14, 2024	SELL	$0.98 - $2.96 $16,814 - $50,787	-17,158 Reduced 98.26%	303 $0

Q2 2024 May 14, 2025	BUY	$1.93 - $3.76 $33,120 - $64,525	17,161 Added 5720.33%	17,461 $37,000
Q2 2024 Oct 17, 2024	BUY	$1.93 - $3.76 $25,663 - $49,996	13,297 Added 319.33%	17,461 $37,000
Q2 2024 Aug 14, 2024	BUY	$1.93 - $3.76 $25,663 - $49,996	13,297 Added 319.33%	17,461 $37,000
Q1 2024 Oct 17, 2024	SELL	$2.78 - $21.53 $36,965 - $286,284	-13,297 Reduced 76.15%	4,164 $13,000
Q1 2024 Aug 16, 2024	BUY	$2.78 - $21.53 $2,315 - $17,934	833 Added 25.01%	4,164 $13,000
Q1 2024 May 15, 2024	BUY	$2.78 - $21.53 $2,315 - $17,934	833 Added 25.01%	4,164 $13,000
Q4 2023 Aug 16, 2024	SELL	$13.92 - $21.0 $196,689 - $296,730	-14,130 Reduced 80.92%	3,331 $68,000
Q4 2023 Feb 13, 2024	BUY	$13.92 - $21.0 $7,600 - $11,466	546 Added 19.61%	3,331 $68,000
Q3 2023 Nov 15, 2023	SELL	$7.58 - $16.08 $299,084 - $634,468	-39,457 Reduced 93.41%	2,785 $44,000
Q2 2023 Aug 14, 2023	SELL	$5.06 - $9.91 $16,647 - $32,603	-3,290 Reduced 7.23%	42,242 $359,000
Q1 2023 May 15, 2023	BUY	$7.94 - $15.6 $33,562 - $65,941	4,227 Added 10.23%	45,532 $449,000
Q4 2022 Feb 14, 2023	BUY	$8.51 - $19.69 $9,122 - $21,107	1,072 Added 2.66%	41,305 $393,000
Q3 2022 Nov 14, 2022	SELL	$7.61 - $22.29 $745 - $2,184	-98 Reduced 0.24%	40,233 $699,000
Q2 2022 Oct 27, 2022	BUY	$7.7 - $18.82 $303,734 - $742,373	39,446 Added 4457.18%	40,331 $313,000
Q2 2022 Aug 15, 2022	BUY	$7.7 - $18.82 $303,734 - $742,373	39,446 Added 4457.18%	40,331 $313,000
Q1 2022 Oct 27, 2022	SELL	$15.0 - $15.4 $591,690 - $607,468	-39,446 Reduced 97.81%	885 $14,000
Q1 2022 May 13, 2022	BUY	$15.0 - $15.4 $13,275 - $13,629	885 New	885 $14,000

Others Institutions Holding ANTX

# of Institutions

Shares Held

7.57M

Call Options Held

Put Options Held

View Full List

About AN2 Therapeutics, Inc.

Ticker ANTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 19,402,700
Market Cap $22.1M
Description
AN2 Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for rare, chronic, and serious infectious diseases. It is developing epetraborole, a once-daily oral treatment for patients with chronic non-tuberculous mycobacterial lung disease. The company was incorporated in 2017 and is headquartered in Menl...

More about ANTX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

News

Stay updated on Morgan Stanley with notifications on news.

Account